abrdn plc Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

abrdn plc acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 28,276 shares of the biotechnology company's stock, valued at approximately $6,218,000. abrdn plc owned approximately 0.06% of United Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of UTHR. DekaBank Deutsche Girozentrale lifted its stake in shares of United Therapeutics by 54.4% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 94,643 shares of the biotechnology company's stock valued at $20,617,000 after purchasing an additional 33,338 shares during the period. Nordea Investment Management AB increased its position in shares of United Therapeutics by 155.2% in the 4th quarter. Nordea Investment Management AB now owns 38,698 shares of the biotechnology company's stock valued at $8,427,000 after buying an additional 23,532 shares in the last quarter. Louisiana State Employees Retirement System bought a new stake in shares of United Therapeutics in the 4th quarter valued at $2,903,000. O Shaughnessy Asset Management LLC increased its position in shares of United Therapeutics by 4.9% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company's stock valued at $520,000 after buying an additional 107 shares in the last quarter. Finally, Vinva Investment Management Ltd increased its position in shares of United Therapeutics by 362.4% in the 3rd quarter. Vinva Investment Management Ltd now owns 5,433 shares of the biotechnology company's stock valued at $1,228,000 after buying an additional 4,258 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm's stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $30,756.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm's stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $30,756.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Nilda Mesa sold 325 shares of the firm's stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total value of $77,285.00. Following the completion of the transaction, the director now owns 5,373 shares of the company's stock, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. Insiders sold 136,990 shares of company stock worth $32,239,641 in the last quarter. Corporate insiders own 12.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on UTHR. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, April 11th. SVB Leerink began coverage on shares of United Therapeutics in a research report on Monday, February 5th. They issued an "outperform" rating and a $330.00 price objective for the company. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research report on Thursday, March 7th. Leerink Partnrs restated an "outperform" rating on shares of United Therapeutics in a research report on Monday, February 5th. Finally, The Goldman Sachs Group upgraded United Therapeutics from a "sell" rating to a "neutral" rating and increased their target price for the stock from $213.00 to $215.00 in a report on Monday, February 12th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $294.25.

United Therapeutics Stock Down 0.9 %

UTHR stock traded down $2.10 during trading hours on Friday, reaching $233.85. 369,691 shares of the stock were exchanged, compared to its average volume of 473,041. The firm's 50-day moving average is $233.74 and its 200-day moving average is $228.76. The company has a market cap of $11.00 billion, a price-to-earnings ratio of 11.79 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating the consensus estimate of $4.28 by $0.08. The company had revenue of $614.70 million during the quarter, compared to analysts' expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. United Therapeutics's revenue for the quarter was up 25.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.67 EPS. On average, equities research analysts expect that United Therapeutics Co. will post 23.45 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.